ICU Medical Inc

ICU Medical Inc(ICUI)股票分析

$161.080

-0.161 (-0.10%)收盤時

Loading chart…
最高
164.000
開盤
161.600
成交量加權均價
161.88
成交量
160.20K
市值
2.89B
最低
160.570
成交金額
25.93M
企業價值/稅息折舊攤銷前利潤(TTM)
13.27

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps.

AI 分析 of ICU Medical Inc (ICUI)

買進

ICU Medical Inc is a good buy right now due to its strong financial performance and positive analyst sentiment. The current price is $162.99, and the forward P/E ratio is 16.95, suggesting the stock is reasonably valued compared to its earnings potential. Additionally, the gross margin has improved significantly to 42.61% in Q2 2026, indicating strong profitability. However, the main risk is the recent insider selling, with the CFO selling shares valued at $1.1 million, which could raise concerns among investors.

分析師評級(5)

上檔空間 +7.71%
持有
2 買進
3 持有
0 賣出
目前: 161.08
最低
172.00
平均
173.50
最高
175.00

Needham

2026-08-07

目標價

$187

買進

Raymond James

2026-08-07

目標價

$200

強烈買進

BTIG

2026-08-07

目標價

$200

買進

BTIG

2026-06-15

目標價

$170

買進

Needham

2026-05-27

目標價

$165

買進

估值指標

ICU Medical Inc(ICUI)目前預期本益比為 16.95,5 年平均預期本益比為 -23.20。

預期本益比

合理
5 年均值 P/E
-23.20
目前P/E
16.95
高估
225.95
低估
-272.35

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
12.92
目前EV/EBITDA
13.27
高估
14.54
低估
11.29

預期股價營收比

合理
5 年均值 P/S
1.62
目前P/S
1.76
高估
1.98
低估
1.26

Alphio AI 對 ICUI 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ICUI

$131.89

情境價格

基

基準

基準 · 50%ICUI

$119.15

情境價格

悲

悲觀

悲觀 · 25%ICUI

$109.89

情境價格

持有 ICUI 的大戶

R

River Road Asset Management, LLC

+ 持有ICUI

-5.12%

3個月報酬率

O

Oberweis Asset Management, Inc.

+ 持有ICUI

-9.06%

3個月報酬率

事件時間軸

2026-08-06 (ET)

17:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $415M-$435M

17:30:00

ICU Medical Q2 Revenue Exceeds Expectations at $551.68M

2026-05-07 (ET)

18:00:00

ICU Medical Reports Q1 Revenue of $530.23M

2026-02-19 (ET)

16:30:00

Company Sees FY26 Adjusted EBITDA of $400M to $430M

16:30:00

ICU Medical Reports Q4 Revenue of $540.7M

資訊

ICUI 常見問題 —— 由 Alphio AI 解答

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ICU Medical Inc is a good buy right now due to its strong financial performance and positive analyst sentiment. The current price is $162.99, and the forward P/E ratio is 16.95, suggesting the stock is reasonably valued compared to its earnings potential. Additionally, the gross margin has improved significantly to 42.61% in Q2 2026, indicating strong profitability. However, the main risk is the recent insider selling, with the CFO selling shares valued at $1.1 million, which could raise concerns among investors.

5 analysts cover ICUI: 2 rate it Buy, 3 Hold and 0 Sell. The average price target is 173.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易